Evidence Files
Cerebrolysin: The Austrian Brain Drug That Austria Doesn't Use
Cerebrolysin is manufactured by an Austrian company in Austria. It's prescribed for millions of patients across China, Ukraine, Russia, and Central Asia recovering from stroke or living with dementia. Austrian hospitals don't use it. This geographic paradox is worth understanding.
Verdict
TRICK (weak evidence)
We searched PubMed and Cochrane Library for cerebrolysin evidence. Clinical trials exist — over 30 RCTs. The Cochrane review (2020) concluded: there is some evidence of benefit for stroke recovery and cognitive function, but the overall quality of evidence is low to moderate, most trials are small, and many have methodological limitations including high risk of bias.
Why it's everywhere except where it's made
Cerebrolysin is a mixture of peptides and amino acids derived from pig brain tissue, manufactured by EVER Neuro Pharma in Austria. The theory behind it: neuropeptides from mammalian brain tissue cross the blood-brain barrier and exert neuroprotective and neurotrophic effects — promoting neuron survival and repair.
The product was developed in the Soviet scientific tradition of biological medicines, where extracts of animal origin were viewed as pharmacologically potent. It found its market in the post-Soviet world and spread to China, which now runs a significant share of clinical trials on it.
The EU regulatory environment requires substantial clinical evidence for prescription medicines — which is why cerebrolysin isn't in Austrian or German stroke protocols. The countries where it's most prescribed have different, generally lower evidence thresholds for drug approval.
What the science actually says
- Cochrane review on dementia (2020) — 15 RCTs reviewed: some signal of benefit on cognitive measures, but high risk of bias across studies; most trials lasted weeks, not years
- Stroke recovery — Cochrane: trials show improvement in some neurological scores; however most are small and have design limitations
- Study geography — approximately 60% of published cerebrolysin trials come from China, Russia, and post-Soviet states; independent Western replication is limited
- Sample sizes — median trial size under 100 patients; compare this to modern stroke drug trials which enroll thousands
- WHO and FDA — not included in WHO essential medicines list; not approved by FDA for any indication
What's prescribed in Kyiv vs. what's used in Vienna
Standard of care in many post-Soviet countries
After stroke: 10-20 days of cerebrolysin IV infusion as a routine neuroprotective measure. For dementia: repeated courses several times a year. Considered a cornerstone of neurological rehabilitation.
Standard of care in Austria (where it's manufactured)
Stroke rehabilitation focuses on early physical and occupational therapy, secondary prevention (antithrombotics, statins, blood pressure control). Neuropeptide infusions are not part of clinical guidelines. The manufacturer's home country doesn't use the manufacturer's product.
Our Conclusion
The cerebrolysin story is more nuanced than outright fraud: there is a signal in the evidence, and the mechanism is biologically plausible. But the signal is weak, the studies are mostly small and geographically concentrated, and the gap between the countries that prescribe it heavily and the countries that apply rigorous evidence standards is telling. If you or a family member has been prescribed cerebrolysin after a stroke, the honest question to ask is: what does the independent evidence say, and what would Western European guidelines recommend instead?
This article is for informational purposes only and does not constitute medical advice. Trick or Treatment analyses the presence of clinical studies in open scientific databases — PubMed and Cochrane Library. The absence of studies in these databases does not automatically mean a drug is ineffective, but it does mean its effectiveness has not been confirmed by evidence-based medicine standards. Any treatment decisions should be made together with your doctor.